Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study
Top Cited Papers
- 17 May 2016
- journal article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 65 (3), 524-531
- https://doi.org/10.1016/j.jhep.2016.05.010
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosisJournal of Hepatology, 2016
- LP13 : Effect of long term viral suppression with sofosbuvir + ribavirin on hepatic venous pressure gradient in HCV-infected patients with cirrhosis and portal hypertensionJournal of Hepatology, 2015
- O008 : Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with child–pugh class B cirrhosis (C-salt part A)Journal of Hepatology, 2015
- LO8 : Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 studyJournal of Hepatology, 2015
- Long‐term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus–related cirrhosisHepatology, 2015
- Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label StudyGastroenterology, 2015
- Patient with decompensated hepatitis C virus–related cirrhosis delisted for liver transplantation after successful sofosbuvir‐based treatmentLiver Transplantation, 2014
- A Proportional Hazards Model for the Subdistribution of a Competing RiskJournal of the American Statistical Association, 1999
- An application of changepoint methods in studying the effect of age on survival in breast cancerComputational Statistics & Data Analysis, 1999
- A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing RiskThe Annals of Statistics, 1988